Search for: "In Re: Pfizer Securities Litigation"
Results 41 - 60
of 104
Sorted by Relevance
|
Sort by Date
14 Sep 2011, 12:07 pm
He is available for general litigation support, medical and marketing record review, and expert witness services including depositions, expert reports and trial testimony.Areas in which Dr. [read post]
22 Jun 2011, 7:09 am
He is available for general litigation support, medical and marketing record review, and expert witness services including depositions, expert reports and trial testimony.Areas in which Dr. [read post]
22 May 2014, 5:00 am
Pfizer, Inc., 2000 WL 1099884, at *2 & n.1 (S.D.N.Y. [read post]
18 Jan 2007, 6:23 am
Most innovative use of technology in a law dept: John Theriault, vice president, and Mary Ann Sarao, director, global security of Pfizer Inc. [read post]
22 Aug 2024, 9:05 pm
WHAT WE’RE READING THIS WEEK In a recent essay published in the Yale Journal on Regulation, Hilary J. [read post]
23 Dec 2013, 5:16 am
Super. 2013), and In re Reglan/Metoclopramide Litigation, 74 A.3d 221 (Pa. [read post]
9 Aug 2012, 5:00 am
Pfizer (femoral stem) Deposition1998-09-18 In re AMS Minnesota Penile Prosthesis Litigation Deposition1998-11-25 Mason v. [read post]
15 Nov 2013, 11:34 am
Pfizer, Inc., 914 F. [read post]
17 Feb 2012, 11:29 am
Pfizer, Inc., 381 F. [read post]
25 Jun 2015, 5:00 am
Pfizer, Inc., 381 F. [read post]
12 Nov 2017, 11:00 pm
Building on its recent decision in In re Petrobras Securities Litigation,[9] the Second Circuit held that a plaintiff need not always offer direct event study evidence of a cause-and-effect relationship between new information and stock price movements before satisfying its burden to prove market efficiency at the class certification stage. [read post]
3 Jan 2013, 2:15 pm
There are important issues at stake re what is “substantial” and what is “fair dealing”. [read post]
21 Apr 2011, 1:36 pm
We have to admit that we’re scratching out heads about a recent decision out of Alabama that – contrary to everything else we’ve seen – concluded that the manufacturer of a branded drug could be liable in a case where it never sold the generic product that was all the plaintiff every took and thereby (allegedly) suffered injury.It’s not like this issue hasn’t been litigated before in Alabama.The first Alabama case we know of to consider the issue… [read post]
4 Nov 2011, 4:00 am
And we’re not just talking about firms that handle so-called “commodity” work. [read post]
25 May 2016, 3:46 pm
” In In re Pfizer Inc. [read post]
2 Aug 2011, 8:59 am
They're not. [read post]
8 Jun 2023, 7:43 am
According to Pfizer, [read post]
8 Jun 2023, 7:43 am
Horizon’s strategy shifted over time, however, with the firm seeking to purchase undervalued therapeutics from bankrupt pharmaceutical companies and then re-launch them. [read post]
11 Apr 2014, 7:41 am
Government is a party to the litigation; and (2) actions in which the rights involved are “integrally related to particular federal government action” or a federal regulatory scheme. 131 S.Ct. at 2611-13. [read post]
30 Sep 2010, 5:58 am
Skeptics have wondered whether litigants might be able to game any substitution. [read post]
